The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy

Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations from microdystrophin expression down to muscle integrity are important and pointed in the right direction. Plus, why the company secured a $200M raise before releasing the data publicly.